Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.35 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4264816 | 0.93 | CYP3A4 (0.38) | CYP3A4HTTSMN1; SMN2SMYD2TDP1 | |
| SCHEMBL10004653 | 0.91 | SMYD2 (0.39) | CYP3A4HTTSMN1; SMN2SMYD2LMNA | |
| SCHEMBL26264750 | 0.91 | SMYD2 (0.39) | CYP3A4HTTSMN1; SMN2SMYD2LMNA | |
| SCHEMBL3860744 | 0.90 | CYP3A4 (0.36) | CYP3A4HTTSMN1; SMN2SMYD2TDP1 | |
| SCHEMBL12799226 | 0.90 | CYP3A4 (0.36) | CYP3A4HTTSMN1; SMN2SMYD2LMNA | |
| SCHEMBL5155697 | 0.90 | CYP3A4 (0.37) | CYP3A4HTTSMN1; SMN2SMYD2TDP1 | |
| SCHEMBL14574000 | 0.90 | CYP3A4 (0.37) | CYP3A4HTTSMN1; SMN2SMYD2TDP1 | |
| SCHEMBL31436999 | 0.88 | CSNK1E (0.38) | CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL25484839 | 0.87 | CYP3A4 (0.36) | CYP3A4HTTSMN1; SMN2SMYD2RIPK1 | |
| SCHEMBL28946557 | 0.85 | SMYD2 (0.41) | CYP3A4HTTSMN1; SMN2SMYD2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203063-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230159563-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. | 2023-05-25 | — | — | US | disclosed |
| EP-1687275-A4 | PYRIDIN-4-YLAMINE COMPOUNDS USEFUL IN THE TREATMENT OF NEUROPATHIC PAIN | MERCK & CO INC (US) | 2009-01-14 | — | — | EP | disclosed |
| US-20070099950-A1 | Pyridin-4-ylamine compounds useful in the treatment of neuropathic pain | AGT SCIENCE LIMITED (GB) | 2007-05-03 | — | — | US | disclosed |
| EP-1687275-A1 | PYRIDIN-4-YLAMINE COMPOUNDS USEFUL IN THE TREATMENT OF NEUROPATHIC PAIN | Merck & Co., Inc. (US) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005051915-A1 | PYRIDIN-4-YLAMINE COMPOUNDS USEFUL IN THE TREATMENT OF NEUROPATHIC PAIN | MERCK & CO., INC. (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203063-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | TYMS, TYMP, DHFR | CYP3A4 45/4885HTT 3232/4885SMN1; SMN2 1154/4885 |
| US-20070099950-A1 | Pyridin-4-ylamine compounds useful in the treatment of neuropathic pain | PER2, CNR2, OPRD1 | CYP3A4 1093/4885HTT 3207/4885SMN1; SMN2 2110/4885 |
| US-20230159563-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | KRAS, NRAS, HRAS | CYP3A4 2707/4885HTT 3233/4885SMN1; SMN2 3697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.